TAZing down metabolic mayhem: siRNAs against liver inflammation and fibrosis in humanized mice

Julian Weihs¹, Milad Rezvani^{1

2

3}

Affiliations

¹ Charité - Charité University Medicine Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Pediatric Gastroenterology, Nephrology and Metabolic Medicine, Berlin, Germany.
² Berlin Institute of Health (Center for Regenerative Therapies, Clinician-Scientist Program), Berlin, Germany.
³ Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

Julian Weihs et al. Mol Ther Methods Clin Dev. 2024.

. 2024 Jan 1;32(1):101182.

doi: 10.1016/j.omtm.2023.101182. eCollection 2024 Mar 14.

Julian Weihs¹, Milad Rezvani^{1

2

3}

¹ Charité - Charité University Medicine Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Pediatric Gastroenterology, Nephrology and Metabolic Medicine, Berlin, Germany.
² Berlin Institute of Health (Center for Regenerative Therapies, Clinician-Scientist Program), Berlin, Germany.
³ Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

1. Wang X., Moore M.P., Shi H., Miyata Y., Donnelly S.K., Radiloff D.R., Tabas I. Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers. Mol. Ther. Method. Clin. Dev. 2023;31 - PMC - PubMed
1. Zabulica M., Srinivasan R.C., Akcakaya P., Allegri G., Bestas B., Firth M., Hammarstedt C., Jakobsson T., Jakobsson T., Ellis E., et al. Correction of a urea cycle defect after ex vivo gene editing of human hepatocytes. Mol. Ther. 2021;29:1903–1917. - PMC - PubMed
1. Tateno C., Kawase Y., Tobita Y., Hamamura S., Ohshita H., Yokomichi H., Sanada H., Kakuni M., Shiota A., Kojima Y., et al. Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice. PLoS One. 2015;10 - PMC - PubMed
1. Ma J., Tan X., Kwon Y., Delgado E.R., Zarnegar A., DeFrances M.C., Duncan A.W., Zarnegar R. A Novel Humanized Model of NASH and Its Treatment With META4, A Potent Agonist of MET. Cell. Mol. Gastroenterol. Hepatol. 2022;13:565–582. - PMC - PubMed
1. Yenilmez B., Wetoska N., Kelly M., Echeverria D., Min K., Lifshitz L., Alterman J.F., Hassler M.R., Hildebrand S., DiMarzio C., et al. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis. Mol. Ther. 2022;30:1329–1342. - PMC - PubMed